Thirty years of HDAC inhibitors: 2020 hindsight

Ho, Terence C. S., Chan, Alex H. Y. and Ganesan, A. ORCID: (2020) Thirty years of HDAC inhibitors: 2020 hindsight. Journal of Medicinal Chemistry, 63 (21). 12460–12484. ISSN 0022-2623

[thumbnail of Accepted_Manuscript]
PDF (Accepted_Manuscript) - Accepted Version
Download (924kB) | Preview


It is now thirty years since the first report of a potent zinc-dependent histone deacetylase (HDAC) inhibitor appeared. Since then, five HDAC inhibitors have received regulatory approval for cancer chemotherapy, while many others are in clinical development for oncology as well as other therapeutic indications. This perspective reviews the biological and medicinal chemistry advances over the last three decades with an emphasis on the design of selective inhibitors that discriminate between the eleven human HDAC isoforms.

Item Type: Article
Uncontrolled Keywords: sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School: Faculty of Science > School of Pharmacy
UEA Research Groups: Faculty of Science > Research Groups > Chemical Biology and Medicinal Chemistry (former - to 2021)
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 07 Jul 2020 23:58
Last Modified: 22 Oct 2022 06:26
DOI: 10.1021/acs.jmedchem.0c00830


Downloads per month over past year

Actions (login required)

View Item View Item